# ðŸ“Š eyentelligence Business Plans - Executive Summary

**Company**: eyentelligence  
**Mission**: Understanding communication from cells to minds  
**Dual Platform Strategy**: cognisom (cellular biology) + eyentell (professional services AI)

---

## Quick Reference

### Documents Created
1. **[BUSINESS_PLAN_STARTUP.md](BUSINESS_PLAN_STARTUP.md)** - Year 0-1 startup phase (30,000+ words)
2. **[BUSINESS_PLAN_3_5_YEAR.md](BUSINESS_PLAN_3_5_YEAR.md)** - Year 2-5 growth plan (20,000+ words)
3. **This summary** - Quick reference and key highlights

---

## The Two Platforms

### Platform 1: cognisom
**What**: GPU-accelerated cellular simulation platform for cancer research  
**Market**: Academic researchers, pharma/biotech, clinical oncologists  
**Model**: Open-source core + commercial licensing + SaaS + grants  
**Positioning**: "The GPU-accelerated standard for cellular biology"

### Platform 2: eyentell
**What**: Privacy-first AI-powered client management for professionals  
**Market**: Solo/small firms in legal, counseling, mental health  
**Model**: SaaS subscriptions ($49-299/month) + implementation services  
**Positioning**: "The privacy-first AI platform for trusted professionals"

### Why Both?
- **Shared technology**: GPU acceleration, vector databases, AI/ML
- **Risk diversification**: Multiple revenue streams, different markets
- **Strategic narrative**: Unique positioning ("cells to minds")
- **Synergies**: Infrastructure, team, brand

---

## 5-Year Revenue Trajectory

| Year | cognisom | eyentell | Combined | Growth |
|------|----------|----------|----------|--------|
| **Year 1** | $265K | $45K | **$310K** | - |
| **Year 2** | $800K-1.3M | $900K-1.35M | **$1.7M-2.65M** | 448-755% |
| **Year 3** | $4M | $2.5M-3M | **$6.5M-7M** | 164-282% |
| **Year 4** | $6M-8M | $6M-10M | **$12M-18M** | 85-157% |
| **Year 5** | $8M-12M | $10M-18M | **$18M-30M** | 50-67% |

**5-Year CAGR**: 150-180%

---

## 5-Year Team Growth

| Year | cognisom | eyentell | Combined |
|------|----------|----------|----------|
| **Year 1** | 2-3 | 2-3 | **4-6** |
| **Year 2** | 5-7 | 6-8 | **11-15** |
| **Year 3** | 12-17 | 18-24 | **30-41** |
| **Year 4** | 20-25 | 30-40 | **50-65** |
| **Year 5** | 25-35 | 40-60 | **65-95** |

---

## Key Milestones by Year

### Year 1: Validation
- âœ… cognisom: Working prototype + $100K-500K grants
- âœ… eyentell: 50-100 customers, $10K-20K MRR
- âœ… Combined: $310K revenue, positive cash flow
- âœ… Team: 4-6 people (contractors + first hires)

### Year 2: Growth
- âœ… cognisom: 100-200 users, first commercial pilots
- âœ… eyentell: 500-700 customers, $70K-100K MRR
- âœ… Combined: $1.7M-2.65M revenue
- âœ… Team: 11-15 people

### Year 3: Scale
- âœ… cognisom: 500-1,000 users, 10-20 enterprise customers
- âœ… eyentell: 2,000-3,000 customers, international expansion
- âœ… Combined: $6.5M-7M revenue, profitable
- âœ… Team: 30-41 people

### Year 4: Market Leadership
- âœ… cognisom: Industry standard in academia, 20-30 pharma customers
- âœ… eyentell: 5,000-7,000 customers, 3+ countries
- âœ… Combined: $12M-18M revenue, 15-20% EBITDA
- âœ… Team: 50-65 people

### Year 5: Dominance & Optionality
- âœ… cognisom: 2,000-5,000 users, FDA clearance path
- âœ… eyentell: 8,000-12,000 customers, market leader
- âœ… Combined: $18M-30M revenue, 15-25% EBITDA
- âœ… Team: 65-95 people
- âœ… Options: IPO, acquisition, or continued growth

---

## Funding Strategy

### Year 1: Bootstrap + Non-Dilutive
- **Personal investment**: $10K-20K
- **Free compute credits**: $50K-150K (NVIDIA, AWS, Google, Azure)
- **Grants**: $100K-500K (NIH, NSF, DoD)
- **eyentell revenue**: $5K-20K MRR
- **Total**: $165K-690K (no dilution)

### Year 2-3: Series A (Optional)
- **Amount**: $5M-10M
- **Timing**: Month 18-24
- **Valuation**: $20M-40M pre-money
- **Dilution**: 20-30%
- **Use**: Team, product, marketing, international

### Year 4-5: Series B (If pursuing aggressive growth)
- **Amount**: $20M-50M
- **Timing**: Month 36-48
- **Valuation**: $100M-300M pre-money
- **Dilution**: 15-25%
- **Use**: Aggressive hiring, international, M&A

### Alternative: Bootstrap to Profitability
- Grow organically with revenue
- Maintain control (no dilution)
- Slower but sustainable growth
- Strategic flexibility

---

## Business Models Compared

### cognisom Revenue Streams

| Stream | Year 1 | Year 3 | Year 5 | % of Total (Y5) |
|--------|--------|--------|--------|-----------------|
| **Grants** | $150K | $700K | $1M-1.5M | 10-15% |
| **Enterprise Licenses** | $0 | $2.2M | $4M-6M | 40-50% |
| **SaaS Platform** | $0 | $500K | $2M-3M | 20-25% |
| **Consulting** | $15K | $600K | $1M-1.5M | 10-15% |
| **Total** | **$165K** | **$4M** | **$8M-12M** | **100%** |

**Key Insight**: Transition from grants to commercial revenue over 5 years

### eyentell Revenue Streams

| Stream | Year 1 | Year 3 | Year 5 | % of Total (Y5) |
|--------|--------|--------|--------|-----------------|
| **Subscriptions** | $40K | $2.3M | $9M-16M | 85-90% |
| **Implementation** | $5K | $200K | $1M-2M | 10-15% |
| **Total** | **$45K** | **$2.5M** | **$10M-18M** | **100%** |

**Key Insight**: Predictable SaaS revenue with high gross margins (80-85%)

---

## Unit Economics

### cognisom (Enterprise Customer)

| Metric | Target |
|--------|--------|
| **ACV** (Annual Contract Value) | $200K-500K |
| **CAC** (Customer Acquisition Cost) | $50K-100K |
| **Gross Margin** | 70-80% |
| **Payback Period** | 6-12 months |
| **LTV:CAC** | 5-10:1 |
| **Churn** | 5-10% annually |

### eyentell (SaaS Customer)

| Metric | Target |
|--------|--------|
| **ARPU** (Avg Revenue Per User) | $100-150/month |
| **CAC** (Customer Acquisition Cost) | $300-500 |
| **Gross Margin** | 80-85% |
| **Payback Period** | 3-6 months |
| **LTV:CAC** | 6-10:1 |
| **Churn** | 3-5% monthly |

---

## Market Opportunity

### cognisom

| Market | Size |
|--------|------|
| **TAM** (Total Addressable Market) | $33B (cancer research + drug discovery) |
| **SAM** (Serviceable Addressable Market) | $5B (computational biology software) |
| **SOM** (Serviceable Obtainable Market - Year 5) | $50M-100M (1-2% of SAM) |

**Target customers**:
- Academic: 1,000+ research institutions globally
- Pharma: Top 50 pharma/biotech companies
- Clinical: 500+ cancer centers

### eyentell

| Market | Size |
|--------|------|
| **TAM** (Total Addressable Market) | $3.6B (professional practice management) |
| **SAM** (Serviceable Addressable Market) | $500M (solo/small firms, privacy-focused) |
| **SOM** (Serviceable Obtainable Market - Year 5) | $30M-50M (6-10% of SAM) |

**Target customers**:
- Legal: 400,000+ solo/small law firms (US)
- Mental health: 200,000+ therapists/counselors (US)
- International: 500,000+ additional (Canada, UK, Australia)

---

## Competitive Positioning

### cognisom: "The GPU-accelerated standard for cellular biology"

**Competitors**:
- PhysiCell/BioDynaMo (agent-based, limited intracellular)
- VCell (CPU-limited, no GPU)
- Covert Lab (single-cell only)
- DeepMind (ML black-box, not mechanistic)

**Advantages**:
- âœ… Only platform with full biochemical fidelity + GPU scale
- âœ… Open-source (community moat)
- âœ… Mechanistic + explainable (not black-box)
- âœ… Multi-scale (molecular to tissue)

### eyentell: "The privacy-first AI platform for trusted professionals"

**Competitors**:
- Clio, MyCase (legal practice management)
- SimplePractice, TherapyNotes (mental health)
- Generic CRMs (Salesforce, HubSpot)

**Advantages**:
- âœ… Privacy-first design (HIPAA-compliant from day 1)
- âœ… AI-powered triage and insights
- âœ… Built for solo/small firms (not enterprises)
- âœ… Cross-vertical (legal + mental health + counseling)

---

## Risk Analysis

### Top 5 Risks & Mitigation

#### 1. Grants not awarded (cognisom)
- **Probability**: Medium (50% success rate)
- **Impact**: High
- **Mitigation**: Apply to 10+ programs, have eyentell revenue as backup, resubmit with feedback

#### 2. Market too small (eyentell)
- **Probability**: Low
- **Impact**: High
- **Mitigation**: Customer interviews validate demand, expand to adjacent markets, pivot if needed

#### 3. Competition intensifies (both)
- **Probability**: Medium-High
- **Impact**: Medium
- **Mitigation**: Build moats (open-source, data, brand), move fast, strategic partnerships

#### 4. Technical challenges (cognisom)
- **Probability**: Low-Medium
- **Impact**: High
- **Mitigation**: Prototype early, consult experts, have fallback approaches, iterative validation

#### 5. Founder burnout
- **Probability**: Medium
- **Impact**: High
- **Mitigation**: Hire contractors early, set realistic timelines, build support network, maintain balance

---

## Success Criteria

### Minimum Viable Success (Year 5)
- âœ… $10M+ combined revenue
- âœ… 5,000+ total customers/users
- âœ… 40+ team members
- âœ… Break-even or profitable
- âœ… Clear market position in both categories

### Target Success (Year 5)
- âœ… $18M-25M combined revenue
- âœ… 8,000-10,000 total customers/users
- âœ… 65-80 team members
- âœ… 15-20% EBITDA margin
- âœ… Market leadership in both categories
- âœ… Strategic optionality (acquisition interest or IPO path)

### Exceptional Success (Year 5)
- âœ… $25M-30M+ combined revenue
- âœ… 10,000-12,000+ total customers/users
- âœ… 80-95 team members
- âœ… 20-25% EBITDA margin
- âœ… Dominant market position
- âœ… IPO-ready or strategic acquisition at $300M+ valuation

---

## Strategic Options (Year 5+)

### Option 1: Continue Independent Growth
- Maintain 30-50% annual growth
- Build towards $100M+ revenue
- Maintain control and flexibility
- **Best if**: Strong profitability, sustainable growth, no competitive pressure

### Option 2: Raise Series B/C
- Raise $20M-50M
- Accelerate growth to 100%+ annually
- Expand internationally, M&A
- **Best if**: Large market opportunity, competitive pressure, need scale

### Option 3: Strategic Acquisition
- Sell to pharma, tech, or healthcare IT company
- Valuation: $150M-500M (8-15Ã— revenue)
- Liquidity for founders/team
- **Best if**: Attractive offer, strategic fit, team wants liquidity

### Option 4: IPO
- Go public at $50M+ revenue
- Valuation: $500M-1B+ (10-20Ã— revenue)
- Maximum liquidity and valuation
- **Best if**: Strong growth, large market, experienced team, Year 6-8 timeline

---

## Immediate Next Steps (Week 1)

### Day 1-2: Company Formation
- [ ] Choose entity type (LLC vs C-corp)
- [ ] File formation documents
- [ ] Get EIN, open bank account

### Day 3-4: Funding Applications
- [ ] NVIDIA Inception (30 min)
- [ ] AWS Cloud Credits (30 min)
- [ ] Google Cloud Credits (30 min)
- [ ] Azure Research Credits (30 min)

### Day 5-7: Technical Setup
- [ ] GitHub repository (cognisom)
- [ ] Documentation (README, ARCHITECTURE)
- [ ] Development environment
- [ ] Project management tools

### Week 2-4
- [ ] cognisom: Single-cell prototype
- [ ] eyentell: Customer interviews (20-30)
- [ ] Business: Accounting, legal, website
- [ ] Funding: Contact program officers

---

## Key Insights & Recommendations

### 1. Dual-Platform Strategy is Powerful
- **Diversification**: Reduces risk, multiple revenue streams
- **Synergy**: Shared technology, team, infrastructure
- **Narrative**: Unique positioning creates competitive moat
- **Optionality**: Multiple paths to success and liquidity

### 2. Bootstrap + Non-Dilutive Funding First
- **Grants**: $500K-2M over 5 years (no dilution)
- **eyentell revenue**: Funds operations, reduces risk
- **Maintain control**: No investors until necessary
- **Raise capital**: Only if accelerates growth significantly

### 3. Focus on Unit Economics
- **cognisom**: High ACV ($200K-500K), long sales cycle, high LTV
- **eyentell**: Lower ARPU ($100-150/month), fast sales, high volume
- **Both**: Strong gross margins (70-85%), efficient CAC, low churn

### 4. Build for Scale from Day 1
- **Technology**: GPU-first, cloud-native, microservices
- **Team**: Hire for growth, not just current needs
- **Processes**: Document, automate, systematize early
- **Culture**: Mission-driven, values-based, scalable

### 5. Timing is Critical
- **cognisom**: GPU computing makes million-cell sims feasible NOW
- **eyentell**: Privacy concerns + AI capabilities converge NOW
- **Market**: Both markets are hot, funding available, competition emerging
- **Action**: Move fast, establish position, build moat

---

## Conclusion

### The Opportunity
eyentelligence is uniquely positioned to build **two category-defining platforms** with:
- **Large markets**: $33B (cognisom) + $3.6B (eyentell)
- **Strong differentiation**: Technical moats + unique positioning
- **Multiple revenue streams**: Grants, licenses, SaaS, services
- **Shared infrastructure**: Efficient operations, synergies

### The Path
- **Year 1**: Validate technology and market ($310K revenue)
- **Year 2**: Achieve product-market fit ($1.7M-2.65M revenue)
- **Year 3**: Scale and establish position ($6.5M-7M revenue)
- **Year 4**: Market leadership ($12M-18M revenue)
- **Year 5**: Strategic optionality ($18M-30M revenue)

### The Outcome
By Year 5, eyentelligence will be:
- **$18M-30M revenue** with 15-25% EBITDA margins
- **10,000+ customers** across both platforms
- **65-95 world-class employees**
- **Market leader** in both categories
- **Strategic options**: IPO, acquisition, or continued growth

### The Ask
**Start now.** The technology is ready, the markets are hot, the timing is perfect.

---

## Additional Resources

### Business Plans
- **[BUSINESS_PLAN_STARTUP.md](BUSINESS_PLAN_STARTUP.md)** - Detailed Year 0-1 plan
- **[BUSINESS_PLAN_3_5_YEAR.md](BUSINESS_PLAN_3_5_YEAR.md)** - Detailed Year 2-5 plan

### Technical Documentation
- **[NVIDIA_GRANT_PREP.md](NVIDIA_GRANT_PREP.md)** - GPU requirements and grant strategy
- **[ARCHITECTURE.md](ARCHITECTURE.md)** - Technical architecture
- **[PROJECT_SUMMARY.md](PROJECT_SUMMARY.md)** - Platform overview

### Funding Materials
- **[funding/NVIDIA_APPLICATION.md](funding/NVIDIA_APPLICATION.md)** - Complete NVIDIA application
- **[funding/GRANT_TARGETS.md](funding/GRANT_TARGETS.md)** - All funding sources
- **[funding/PITCH_DECK_CONTENT.md](funding/PITCH_DECK_CONTENT.md)** - Investor pitch deck

---

**"The best way to predict the future is to invent it." â€” Alan Kay**

**Let's invent a future where:**
- Cancer treatments are predicted before they're prescribed
- AI systems form genuine, trustworthy relationships
- Biological understanding guides intelligent design
- Communication is understood from cells to minds

**The time is now. Let's build.** ðŸš€ðŸ§¬ðŸ’»

---

**Document Version**: 1.0  
**Created**: November 2024  
**Total Word Count**: 55,000+ words across all business plan documents
